EA202090683A3 - Способы и композиции для лечения рака - Google Patents

Способы и композиции для лечения рака

Info

Publication number
EA202090683A3
EA202090683A3 EA202090683A EA202090683A EA202090683A3 EA 202090683 A3 EA202090683 A3 EA 202090683A3 EA 202090683 A EA202090683 A EA 202090683A EA 202090683 A EA202090683 A EA 202090683A EA 202090683 A3 EA202090683 A3 EA 202090683A3
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
cancer treatment
cancer
treatment
Prior art date
Application number
EA202090683A
Other languages
English (en)
Other versions
EA202090683A2 (ru
Inventor
Лаура Соусек
Мари-Эв Болье
Original Assignee
Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн filed Critical Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Хеброн
Publication of EA202090683A2 publication Critical patent/EA202090683A2/ru
Publication of EA202090683A3 publication Critical patent/EA202090683A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к доминантно-негативному мутанту Myc, называемому Omomyc, для применения в медицине и для применения в профилактике и/или лечении рака. Изобретение также относится к слитому белку, содержащему Omomyc, и к его фармацевтической композиции и к применению в медицине, и в частности, для лечения рака.
EA202090683A 2013-05-07 2014-05-07 Способы и композиции для лечения рака EA202090683A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20130382167 EP2801370A1 (en) 2013-05-07 2013-05-07 Methods and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
EA202090683A2 EA202090683A2 (ru) 2020-06-30
EA202090683A3 true EA202090683A3 (ru) 2020-09-30

Family

ID=48366303

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690159A EA035463B1 (ru) 2013-05-07 2014-05-07 Способы и композиции для лечения рака
EA202090683A EA202090683A3 (ru) 2013-05-07 2014-05-07 Способы и композиции для лечения рака

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201690159A EA035463B1 (ru) 2013-05-07 2014-05-07 Способы и композиции для лечения рака

Country Status (25)

Country Link
US (2) US10370434B2 (ru)
EP (4) EP2801370A1 (ru)
JP (2) JP6722103B2 (ru)
KR (1) KR102324116B1 (ru)
CN (1) CN105378084B (ru)
AU (1) AU2014264642B2 (ru)
BR (2) BR112015028115B1 (ru)
CA (1) CA2911863A1 (ru)
CY (1) CY1121849T1 (ru)
DK (1) DK2994533T3 (ru)
EA (2) EA035463B1 (ru)
ES (1) ES2733515T3 (ru)
HK (2) HK1219756A1 (ru)
HR (1) HRP20191330T1 (ru)
HU (1) HUE045615T2 (ru)
IL (2) IL242483B (ru)
LT (1) LT2994533T (ru)
ME (1) ME03509B (ru)
MX (1) MX370792B (ru)
PL (1) PL2994533T3 (ru)
PT (1) PT2994533T (ru)
RS (1) RS59276B1 (ru)
SG (2) SG10201709101VA (ru)
SI (1) SI2994533T1 (ru)
WO (1) WO2014180889A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
EP3411387A4 (en) * 2016-02-03 2019-12-04 Kennesaw State University Research And Services Foundation Inc. SIGNAL MOLECULES USEFUL AS CELL PENETRATION AGENTS
US20190135868A1 (en) * 2016-04-29 2019-05-09 The University Of Chicago Synthetic dna binding domain peptides and uses thereof
EP3269734A1 (en) * 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
CN106591335A (zh) * 2016-11-08 2017-04-26 安徽省农业科学院水稻研究所 一种密码子植物化改造的LbCpf1基因及其应用
CN111405903A (zh) * 2017-09-08 2020-07-10 Idp研发制药有限公司 多发性骨髓瘤的新疗法
US20200354411A1 (en) * 2017-11-29 2020-11-12 Agency For Science, Technology And Research Chimeric Molecule for Targeting c-Myc in Cells
JP2021521126A (ja) * 2018-04-09 2021-08-26 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System エキソソームを用いたがん遺伝子に対する治療的な標的指向化の方法
CN113557035A (zh) * 2019-01-12 2021-10-26 卫理公会医院 自组装肽纳米颗粒和其用途
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
BR112021018506A2 (pt) 2019-03-19 2021-11-30 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Terapia de combinação para tratamento do câncer
KR102221227B1 (ko) 2019-05-07 2021-03-03 김영화 공급자 연동과 다국어 지원 기능을 구비한 쇼핑몰 플랫폼 제공 장치 및 그 방법
WO2021041953A1 (en) * 2019-08-30 2021-03-04 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof
CN115925975B (zh) * 2022-08-03 2024-09-17 山东大学 一种靶向肿瘤干细胞的car-mφ体内外编辑制备方法以及其应用
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment
EP4446742A1 (en) 2023-04-14 2024-10-16 Peptomyc, S.L. Method for assessing or monitoring the response to a cancer treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US5322801A (en) 1990-04-19 1994-06-21 The General Hospital Corporation Protein partner screening assays and uses thereof
JPH07505054A (ja) 1992-03-23 1995-06-08 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド ロイシンジッパー
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP2477985B1 (en) * 2009-09-15 2018-11-07 BlueLink Pharmaceuticals, Inc. Crlx101 for use in the treatment of cancer
DE102009052866A1 (de) * 2009-11-13 2011-05-19 Bizerba Gmbh & Co. Kg Schneidemaschine
US9155724B2 (en) 2010-02-05 2015-10-13 Whitehead Institute For Biomedical Research Combination methods for treatment of disease
RU2556800C2 (ru) * 2010-06-14 2015-07-20 Ф.Хоффманн-Ля Рош Аг Пептиды, проникающие в клетки, и их применения
US9241920B2 (en) * 2011-10-27 2016-01-26 New York University Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP2801370A1 (en) 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
ES2733515T3 (es) 2019-11-29
CN105378084A (zh) 2016-03-02
SG11201509131VA (en) 2015-12-30
IL273090A (en) 2020-04-30
HRP20191330T1 (hr) 2019-10-18
US20190382468A1 (en) 2019-12-19
US10370434B2 (en) 2019-08-06
WO2014180889A1 (en) 2014-11-13
EP2994533B1 (en) 2019-05-01
US20160122415A1 (en) 2016-05-05
HUE045615T2 (hu) 2020-01-28
BR112015028115B1 (pt) 2023-11-21
RS59276B1 (sr) 2019-10-31
LT2994533T (lt) 2019-08-12
JP6790148B2 (ja) 2020-11-25
AU2014264642A1 (en) 2015-11-19
AU2014264642B2 (en) 2020-09-17
HK1219756A1 (zh) 2017-04-13
EA201690159A1 (ru) 2016-05-31
EP2801370A1 (en) 2014-11-12
CN105378084B (zh) 2019-07-05
PT2994533T (pt) 2019-08-05
IL273090B (en) 2022-06-01
CA2911863A1 (en) 2014-11-13
HK1251494A1 (zh) 2019-02-01
IL242483B (en) 2020-03-31
KR102324116B1 (ko) 2021-11-11
MX2015015518A (es) 2016-07-21
EA202090683A2 (ru) 2020-06-30
SI2994533T1 (sl) 2019-09-30
ME03509B (me) 2020-04-20
MX370792B (es) 2020-01-08
KR20160013058A (ko) 2016-02-03
WO2014180889A8 (en) 2015-06-18
DK2994533T3 (da) 2019-07-01
JP6722103B2 (ja) 2020-07-15
CY1121849T1 (el) 2020-07-31
BR122020017819B1 (pt) 2023-11-21
JP2019147792A (ja) 2019-09-05
EA035463B1 (ru) 2020-06-19
EP3338789A1 (en) 2018-06-27
EP2994533A1 (en) 2016-03-16
BR112015028115A2 (pt) 2017-10-17
EP3545966A1 (en) 2019-10-02
PL2994533T3 (pl) 2020-03-31
JP2016520056A (ja) 2016-07-11
SG10201709101VA (en) 2017-12-28
US11339205B2 (en) 2022-05-24

Similar Documents

Publication Publication Date Title
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
MY187540A (en) Compounds active towards bromodomains
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12014501991B1 (en) Phenicol antibacterials
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний